CONVERSION CHEMOTHERAPY WITH A MODIFIED FLOX REGIMEN FOR BORDERLINE OR UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER

Abstract

metastasectomy for fluorouracil, leucovorin, and oxaliplatin (mFLOX (mFLOX)) (mFLOX (mFLOX)
In patients with CRC-derived liver metastases receiving conversion chemotherapy with a regimen
Evaluation of treatment outcomes of PG / NEOP liver metastases. Materials and methods: hepatic metastasis
one-centered retrospective analysis of patients. PG / NEOP from CRC treated with mFLOX chemotherapy (mFLOX):
with surgery: B / U disease was diagnosed with at least one: more than four injuries, liver damage arteries
or the involvement of portal vein or bile structures. Results: PG / NEOP meets the criteria for liver metastases
35% of the 54 consecutive patients were evaluated. More than four liver injuries in 35% of patients, 16 (29%) -
primary vascular damage. structures, 16 (29%) - bile ducts. Surgery in all patients after chemotherapy
operation was performed, 42 (77%) R0 resections were performed. 37.2 months after median follow-up, from median disease
survival (PFS) was 16.9 months and median total survival (OS) was 68.3 months. With resection R0
in comparison, R1-R2 resections were associated with PFS and OS (PFS: risk level 2.65; P = 0.007; OS: risk factor 2.90;
P = 0.014). Conclusion: PG / NEOP in the liver from CRC using conversion chemotherapy using mFLOX mode (mFLOX)
treatment of metastases, high frequency of R0 resection, and positive survival outcomes. mFLOX
(mFLOX) is a cheaper option for conversion chemotherapy, among other proposed options.